Kaiser Washington Vaccine and Treatment Evaluation Unit – DMID 21-0004

凯撒华盛顿疫苗和治疗评估单位 — DMID 21-0004

• 批准号: 10523479
• 负责人: LISA A JACKSON
• 金额: $ 211.45万
• 依托单位: KAISER FOUNDATION RESEARCH INSTITUTE
• 依托单位国家: 美国
• 财政年份: 2022
• 资助国家: 美国
• 起止时间: 2022-04-07 至 2023-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10523479
• 关键词: 2019-nCoV; Biological Assay; COVID-19 vaccine; Child; Evaluation; Funding; Postpartum Period; Pregnancy; Protocols documentation; Research Institute; Safety; United States National Institutes of Health; Vaccines; Washington; Work; clinical research site; immunogenicity

The 21-0004 protocol will evaluate the safety and immunogenicity of SARS-CoV-2 administered during pregnancy or postpartum. The Seattle Children’s Research Institute, a subcontractor to the Kaiser Washington VTEU, has been selected to perform SARS-CoV-2 pseudovirus neutralization assays for the 21-0004 trial. The NIH will provide funds for the assay work to the Kaiser Washington VTEU, which will then provide funds to the Seattle Children’s Research Institute via the existing subcontract. Kaiser Washington is not a clinical site for the 21-0004 trial and the work of the subcontractor is the only involvement of Kaiser Washington in that trial.

21-0004方案将评价在治疗期间给予SARS-CoV-2的安全性和免疫原性。 怀孕或产后。西雅图儿童研究所是凯撒华盛顿号的分包商 已选择VTEU进行21-0004试验的SARS-CoV-2假病毒中和试验。的 NIH将向凯撒华盛顿VTEU提供检测工作的资金，凯撒VTEU将向 西雅图儿童研究所通过现有的电子邮件。凯泽华盛顿不是一个临床网站， 21-0004审判和分包商的工作是凯撒华盛顿在该审判中的唯一参与。